Watson Biological: In the first half of the year, net profit returned to her mother was 421 million yuan, an increase of 31.9% year -on -year

On August 10, 2022, the A -share company Watson Bio (300142.SZ) disclosed the semi -annual report that the company's operating income in the semi -annual 2022 year was 2.348 billion yuan, an increase of 73.96%year -on -year;Increased by 31.90%; basic earnings per share were 0.26 yuan.

In the first half of the year, the subsidiary Yuxi Watson's 13 -valent pneumonia combined vaccine was approved and issued 37.315 million doses, an increase of 39.68%over the same period last year.

In the first half of the year, some of Yuxi Watson's product production line was renovated due to the rectification of the WHO-PQ project. In addition, the adjustment of related product production plans, which led to a large decline in the number of partial issuance of some vaccine products.And approval will be restored.

- END -